The Immune-Aging Project

What We Do

The Immune-Aging Project is a global non-profit focused on shared challenges that influence progress in immune-aging field.

Laboratories, clinicians, companies, funders, and non-profits all contribute to the advancement of immune-aging science. Many challenges that shape progress are shared across organizations rather than confined to any single one.

These include how knowledge is shared, how evidence is interpreted, and how findings remain meaningful as the field evolves.

Our work is organized through two programs:

Science Communication Program. Bringing scientists, evidence, and ideas into structured conversations that broaden the reach of rigorous science.

Explore Science Communication →

Continuum Program. Working on the challenges that determine whether immune-aging evidence can remain meaningful, accumulate over time, and support future translation.

A stylized abstract image representing the flow of scientific data

Our Thinking: The Collaborative Science of Longevity

Late-life health loss often attributed to aging is not our inevitable fate. We believe that by elucidating the fundamental mechanisms of immune aging, we can translate that biology into actionable interventions and engineer a future of healthy longevity.

To achieve this, we believe in a community-driven approach. Finding the right collaborator (whether a cross-disciplinary researcher, a funder, or an industry partner) is like finding a substrate for an enzyme.

We aim to facilitate collaborative science and data sharing to help each other overcome bottlenecks in scientific work and bring fundamental science and industry work together.

Leadership

The Immune-Aging Project is led by scientists with experience spanning aging biology, immunology, and program development.

Amit Agrawal, Ph.D.

Executive Director

An aging biologist and engineer whose work combines experimental biology, quantitative analysis, and systems thinking. His research at the Weizmann Institute showed that senescent cells become harder for the body to remove with age, identified a PD-L1-based mechanism that helps them evade immune surveillance, and characterized the diversity of senescent cells that arise naturally in tissues.

Julia Magdalena Majewska, Ph.D.

Scientific Program Director

An immuno-oncologist at INSERM bridging the gap between cancer biology and aging. Her research at the Weizmann Institute of Science demonstrated that senescent cells hijack the PD-L1 checkpoint to evade clearance, establishing a direct therapeutic link between cancer immunotherapy and longevity science.